Answers are grounded in this paper and cite their sources.
Demonstrates a new probe for analyzing prenylation inhibitors, indicating its potential for therapeutic development.
Protein prenylation is a critical post-translational modification that controls many cancer-related signalling pathways and represents an important therapeutic target currently lacking effective pharmacological agents. Here, we establish the fluorescent prenyl diphosphate analogue MANT-O-GPP as a multipurpose probe for simultaneous analysis of ligand binding and catalysis in geranylgeranyltransferase I (GGTaseI) and farnesyltransferase (FTase). Using a tryptophan-to-MANT-O-GPP FRET assay, we found that MANT-O-GPP bound to GGTaseI and FTase with high affinity and reported occupancy of the isoprenoid donor site, as confirmed by displacement with the native substrates. In parallel, a FRET-based activity assay employing CFP-tagged protein substrates enabled direct monitoring of prenyl transfer and product formation. Notably, the known inhibitor L-778123 blocked catalysis without displacing MANT-O-GPP, demonstrating that the combined platform distinguishes prenyl-site competitors from inhibitors acting through the adjacent protein-substrate region. This fluorescence-based system provides a practical, mechanistically informative, and high-throughput-compatible platform for prenyltransferase inhibitor discovery.
No takes yet. Share an insight, caveat, or question.
Yehia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: